Final Results of the KRISTINE Trial in HER2-Positive Breast Cancer

Leggi l'articolo originale


This phase III trial tested T-DM1 plus pertuzumab vs chemotherapy and dual HER2 blockade in patients with HER2+ breast cancer.

Lascia un commento